Expansion Opportunity Investing $50 million to expand PET radiopharmaceutical manufacturing capacity signals imminent supply growth and capacity to meet rising demand; sales teams should align with operators seeking reliable, scalable production for imaging and therapeutic radiopharmaceuticals.

Mobile Access Launch of RUBY mobile solutions post FDA approval expands PET imaging access; target radiology networks, clinics, and ambulatory centers expanding their PET imaging programs.

Strategic Partnerships Recent collaborations with Evergreen Theragnostics and Isotopia Molecular Imaging indicate a pattern of channel and kit-based distribution; explore co-selling, distribution partnerships, and bundled offerings with U.S. and Canadian healthcare providers.

Alpha Radiopharma Active development of alpha radiopharmaceuticals with CNL collaboration suggests entry points for specialized therapeutic agents; position with nuclear medicine departments exploring novel therapeutic options and regulatory-ready products.

Global Diagnostics Portfolio Broad portfolio spanning diagnostic and therapeutic radiopharmaceuticals across cardiology, oncology, pulmonology, and endocrinology highlights cross-sell potential to multi-specialty hospitals and health systems seeking integrated imaging and treatment solutions.